Tvardi Therapeutics updates STAT3 fibrosis-focused clinical pipeline

Tvardi Therapeutics ( (TVRD) ) has issued an announcement.

In January 2026, Tvardi Therapeutics provided an overview of its clinical pipeline and recent progress in targeting STAT3 for fibrosis-driven diseases, highlighting TTI-101 and TTI-109 as key assets. The company reported that topline data from the REVERTIPF Phase 2 trial of TTI-101 in idiopathic pulmonary fibrosis, released on October 13, 2025, showed overlapping changes in forced vital capacity between treatment and placebo groups, with placebo performance exceeding historical expectations and high variability across cohorts, while treatment-emergent adverse events led to early discontinuations and fewer patients evaluable at 12 weeks. Tvardi also outlined upcoming milestones, including additional IPF data reported in January 2026 and planned Phase 1b/2 topline data in hepatocellular carcinoma and Phase 1 healthy volunteer data for TTI-109 in the first half of 2026, underscoring both the scientific rationale for STAT3 inhibition and the operational execution challenges in advancing its clinical programs.

The most recent analyst rating on (TVRD) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Tvardi Therapeutics stock, see the TVRD Stock Forecast page.

Spark’s Take on TVRD Stock

According to Spark, TipRanks’ AI Analyst, TVRD is a Underperform.

Cara Therapeutics’ overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues and negative profitability. The technical analysis also suggests a bearish trend, with the stock trading below major moving averages. Valuation metrics further reflect the company’s financial struggles, with a negative P/E ratio and no dividend yield. While there are some positive developments in clinical trials, the recent setback in the Phase 2 trial underscores ongoing challenges.

To see Spark’s full report on TVRD stock, click here.

More about Tvardi Therapeutics

Tvardi Therapeutics is a biotechnology company focused on developing small-molecule inhibitors of STAT3, a central mediator in fibrosis-driven and proliferative diseases, with a particular emphasis on idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC). Its lead candidates include TTI-101, aimed at treating fibrotic and proliferative conditions, and TTI-109, a prodrug designed to enhance delivery and tolerability of the active STAT3 inhibitor TTI-101, targeting fibrotic diseases and fibrotic cancers.

Average Trading Volume: 181,472

Technical Sentiment Signal: Sell

Current Market Cap: $43.44M

For a thorough assessment of TVRD stock, go to TipRanks’ Stock Analysis page.